Bristol-Myers Squibb: In phase 3 breast cancer studies, isabemumab reduced the risk of disease progression or death by 59%.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.